PATENT CLAIM ANALYSIS

Application Number: 16405581
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-10
Patent Classification: ["514", "307000"]

Abstract:
Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

Claim (Index 38):
The method of  claim 36 , wherein said HDAC8 inhibitor is a compound of formula (I): wherein:\n R 1  is substituted or unsubstituted C 1 -C 20  alkyl substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C 3 -C 7  cycloalkyl, substituted or unsubstituted 3 to 7 membered heterocycloalkyl, substituted or unsubstituted C 3 -C 7  aryl, or substituted or unsubstituted 3 to 7 membered heteroaryl; and \n R 2  is substituted or unsubstituted C 1 -C 20  alkyl, substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C 3 -C 7  cycloalkyl, substituted or unsubstituted 3 to 7 membered heterocycloalkyl, substituted or unsubstituted C 3 -C 7  aryl, or substituted or unsubstituted 3 to 7 membered heteroaryl.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 100.0
- Lexical Diversity: 1.0625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15042012', '16027029', '14992396', '15421258', '15123232']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7901959445758129
- 35 USC 102 Novelty (BERT): 0.6935010880831802
- Combined Prediction Score: 0.7805264589265497
- Mean Citation Score: 512.8317040000002
- Max Citation Score: 827.5081
- Similarity Product: 669.8317835599541

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test